MedTrace Logo

Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation

NCT01666769 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-11-05

No results posted yet for this study

Summary

Determine proper dosing of micafungin in children supported with extracorporeal membrane oxygenation (ECMO).

Conditions

  • Invasive Candidiasis

Interventions

DRUG

Micafungin

4 mg/kg/day

DRUG

Micafungin

8 mg/kg/day

DRUG

Micafungin

Standard of care Dosing

Sponsors & Collaborators

  • Kevin Watt

    lead OTHER

Principal Investigators

  • Kevin Watt, MD · Duke Clinical Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2016-02-02
Completion
2016-02-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01666769 on ClinicalTrials.gov